Selective inhibition of gene expression by
RNA interference (
RNAi) and wider oligonucleotide methods hold the potential to address significant unmet medical needs with importance across major disease areas such as cancer, genetic disorders, cardiovascular disease and autoimmune disorders. Recent advances in small interfering
RNA delivery and target selection provide unprecedented opportunities for clinical translation and positioning in the market place.
This conference offers the opportunity to engage with strategies for advancing
RNAi–based therapies for rare and major diseases through devlopment and clinical trials to market, case study updates on approaches to optimising
RNAi formulation and delivery and hear lessons learned through successful submissions from regulators.
Benefits of Attending
- Take away best practice learning on efficient and targeted efforts to maximise return on investment
- Hear key case studies from leading companies and gain the edge in confronting the challenges of RNAi R&D
- Discover the latest clinical data in RNAi and ASO medicine including the latest single strand antisense approaches
- Review new conjugate/aptamer/lipid/polymer/nanoparticle delivery systems to enhance the efficacy and bioavailability of compounds
- Update on the state of CRISPR technology for therapy
- Enhance knowledge of IP and regulatory affairs
Plus an Interactive Half-Day Post-Conference Workshop | Wednesday 18th February
RNAi therapeutics; appreciating the gap in delivery from preclinical studies to clinical successWorkshop Leaders: Prof Andrew David Miller, Professor of Organic Chemistry & Chemical Biology and CSO, GlobalAcorn Ltd
Terry Wilkins, Yorkshire Forward Professor of Nanomanufacturing Innovation, CEO, NanoManufacturing Institute (NMi), University of Leeds
8.30am – 12.30pm
Speakers
- Annemieke Aartsma-Rus, Associate Professor, Leiden University Medical Center
- Axel Vater, VP Drug Discovery and Preclinical Research, Noxxon Pharma AG
- Bård Smedsrod, Chief Scientific Officer, D'Liver
- Bo Rode Hansen, VP, Drug Discovery & Alliance, Roche
- Claude Paul Malvy, Professor, Universite Paris Sud
- Covadonga Paneda, R&D Manager, Sylentis
- David Blakey, Chief Scientist, AstraZeneca
- Dirk Haussecker, Consultant, RNA therapeutics
- Giles Campion, Chief Medical Officer and SVP R&D, Prosensa Therapeutics
- James Legg, Patent Attorney, Boult Wade Tennant
- Jesper Wengel, Professor, BioNEC Center Director, University of Southern Denmark
- Joerg Kaufmann, Chief Scientific Officer, Silence Therapeutics
- Matthew Wood, Professor of Neuroscience and Assistant Head of Research, University of Oxford
- Michael Kormann, Group Leader, Pediatric Infectiology and Immunology, Eberhard-Karls-University Tuebingen
- Nagy Habib, Chairman and Co-Founder, MiNA Therapeutics
- Rodger Novak, CEO, CRISPR Therapeutics
- Ryszard Kole, Distinguished Scientist, Sarepta Therapeutics
- Steffen Panzner, Managing Director, Lipocalyx
- Stephen Hart, Professor in Molecular Genetics, UCL
- Steven Hood, Director, Scinovo, GSK
- Sven Klußmann, Co-Founder & Chief Technology Officer, Noxxon Pharma
- Victor Kotelianski, Director of the Centre for Research, Education and Innovation, Skolkovo Institute of Science and Technology
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right side of the page.
Venue
The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.
Who Should Attend
Our 2015 RNA Therapeutics event is a must attend for the following:
- Research Scientist
- Director
- Chief Scientific Ofiicer
- Professor of Medicine
- PhD student
- Academic research staff
- Formulation Scientist
- Research assistant
- Clincal scientist
- Biomedical scientist
- Biotechnology
- Post Doctoral Fellow
- Clinical Investigator
- Pharmacologist
- Medicinal Chemist
- Formulation scientist
Venue
Marriott Hotel, Regents Park128 King Henry's Road
London, NW3 3ST
United Kingdom
